Boston Scientific BSX Urology — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Boston Scientific's urology — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Boston Scientific's urology — net sales?
- Boston Scientific (BSX) reported urology — net sales of $646M in Q1 2026.
- How has Boston Scientific's urology — net sales changed year-over-year?
- Boston Scientific's urology — net sales increased by 2.1% year-over-year, from $633M to $646M.
- What is the long-term trend for Boston Scientific's urology — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's urology — net sales has grown at a 14.4% compound annual growth rate (CAGR), from $1.58B to $2.71B.
- What does urology — net sales mean?
- The total revenue earned from selling products specifically designed for urological and pelvic health treatments.
- How do you interpret urology — net sales?
- An increase indicates strong product adoption, successful market penetration, or expansion of the urology portfolio, while a decrease may signal competitive pressure or reduced demand for these specific medical procedures.
- How does urology — net sales compare across companies?
- Comparable to specialized medical device segment revenues at peer firms, often evaluated against broader medtech growth benchmarks and specific urology market growth rates.